A recent Cytel webinar clarifies common misunderstandings regarding synthetic control arms (SCAs). The use of real world data (RWD) to forgo traditional clinical trials is attractive, but requires a thorough understanding of the purpose of and challenges associated with SCAs. Two common criticisms of SCAs are unmeasured confounding effects and missing data.
“Although synthetic control arm studies have a lot of promise, there are often several misconceptions about them in the industry. In a recent Cytel webinar, our panel of expert speakers from Roche, CIOX Health and Cytel, share their insights and bust industry myths around the use of synthetic controls in research and regulatory applications. In this four-part blog series, we will dispel these myths for you, beginning with the myth surrounding SCA’s regulatory acceptance.” Watch the on-demand webinar here.
(Source: Mansha Sachdev, Cytel, 6/10/21)